ArticleInternational journal of yoga
Effect of 12-week Practice of Anulom Vilom Pranayama as Adjunctive Therapy on the Cardiac Autonomic Balance, Cognition, Psychological Status, and Quality of Life in Individuals with Mild-to-Moderate Parkinson's Disease: A Randomized Controlled Trial.
Article in International journal of yoga. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Patients with Parkinson's disease (PD) commonly experience cardiac autonomic dysfunction, cognitive impairment, and psychological disturbances. Limitations in current treatment modalities warrant the need for simple, cost-effective adjuvant therapies. Pranayama, a fundamental component of yoga, has been proven to be beneficial for several medical disorders. Aim: This study aimed to assess the effects of the 12-week practice of Anulom Vilom Pranayama (AVP) or Alternate Nostril Breathing (ANB) as an adjunctive therapy on the cardiac autonomic balance, cognition, psychological status, and quality of life (QoL) in individuals with PD. Subjects and Methods: This randomized controlled trial involved 86 individuals (55 males, 31 females, aged 35-70 years) with mild-to-moderate PD. Participants were randomized into the control group receiving conventional treatment only or the test group receiving AVP as an adjunctive therapy to the conventional treatment. Cardiac autonomic status (heart rate variability [HRV]), cognition (P300, Reaction Time), affect, psychological status, and QoL were assessed in all the participants at baseline and after 12 weeks of respective intervention. Statistical Analysis: The change in study parameters (0-12 weeks) was compared between the control and test groups using the Mann-Whitney Results: The test group revealed significantly high total HRV (standard deviation of normal-to-normal intervals [SDNN], total power) and HRV indices of cardiac parasympathetic activity (square root of the mean of the sum of the squares of differences between adjacent NN intervals [RMSSD], percentage of NN50 [pNN50], HF power, HF normalized unit) and significantly low HRV indices of cardiac sympathetic activity (LF normalized unit) and cardiac sympathovagal balance (LF/HF ratio) compared to the control group. Similarly, significant improvement in cognition, psychological status, and QoL was also observed in the test group. While significant correlations were observed between the change in LF/HF ratio and QoL in both the groups, a significant correlation between the change in LF/HF ratio and positive affect was observed only in the test group. Conclusions: Twelve weeks of practice of AVP significantly improved the cardiac sympathovagal balance, cognition, positive affect, and QoL and decreased the negative affect, depression, stress, and anxiety in patients with mild-to-moderate PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.